A More Reliable Diagnosis Of Neuroendocrine Tumors

December 12, 1998

High blood levels of chromogranin A point to the presence of slowly progressive gastrointestinal neuroendocrine tumors. Although tentatively used by clinicians, this diagnostic tool lacked reliability because chromogranin A is degraded when released into the circulation. This obstacle has been overcome by the INSERM team headed by Dominique Aunis (U338, Strasbourg) working in cooperation with CIS Bio International. This innovative assay method, which is already commercially available, is the subject of a patent application submitted by CIS Bio international.

A few years ago, Dominique Aunis' team were working on the structure of chromogranin A and found that a fragment of the molecule was protected from protein breakdown. It is the same protected fragment that is measured in the new chromogranin A assay based on radioimmunologic methodology and monoclonal antibodies.

Chromogranin A can now be measured precisely and reliably in peripheral blood. By examining changes in the circulating chromogranin A concentration, clinicians can follow the outcome of gastrointestinal neuroendocrine tumors. Long-term follow-up of these malignancies is important, given that they progress very slowly. The same researcher team are trying to determine if chromogranin A might also serve as a diagnostic marker for other types of neuroendocrine tumor, such as small-cell lung cancer in smokers. If so, this new assay method would find a number of key applications.
-end-
For further information :

References
A new human chromogranin A (Cg A) immunoradiometric assay involving monoclonal antibodies against the unprocessed central domaine (145-245)

Degorce F.1, Goumon Y.2, Jacquemart L.1, Vidaud C.1, Bellanger L.1, Pons-Anicet
D.1, Seguin P.1, Metz-Boutigue M.-H.2, Aunis D.2

1CIS bio international, Division In Vitro Technologies, Bagnols-sur-Cèze, France
2INSERM unit 338, Strasbourg, France

British Journal of Cancer, vol 79, issue 1, pp 65-71, 12th december 1998



French National Institute for Health and Medical Research (INSERM)

Related Assay Based Articles from Brightsurf:

New assay screens human brain organoids, doubles known candidate genes for microcephaly
A new tissue screening assay for human cerebral organoids identified 25 additional candidate genes for microcephaly, nearly doubling the number of currently known genes linked to the rare neurological condition.

Graphene-based memory resistors show promise for brain-based computing
As progress in traditional computing slows, new forms of computing are coming to the forefront.

Smart fluorescent molecular switches based on boron-based compounds
Scientists have developed extremely stable molecular switches of high luminosity that self-assemble into 1D nanostructures and form gel-like materials.

A simple, cost-effective molecular assay may help manage growing spread of drug-resistant gonorrhea
A drug-resistant strain of the Neisseria (N.) gonorrhoeae has emerged around the world with the potential to make gonorrhea untreatable.

Study shows proof of concept of BioIVT HEPATOPAC cultures with targeted assay to evaluate bioactivation potential and drug-induced liver injury (DILI) risk
New in vitro Bioactivation Liver Response Assay used HEPATOPAC model to demonstrate utility of in vitro transcriptomic signature-based strategy in preclinical DILI risk assessment.

Point-of-care biomarker assay for traumatic brain injury
Intracranial abnormalities on CT scan in patients with traumatic brain injury (TBI) can be predicted by glial fibrillary acidic protein (GFAP) levels in the blood.

New streamlined assay can improve prenatal detection of alpha-thalassemia
In a report in The Journal of Molecular Diagnostics, published by Elsevier, researchers describe a rapid, accurate novel assay for nondeletional alpha-thalassemia genotyping based on one-step nested asymmetric PCR melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening.

Construction of sintering resistant Pt based catalyst based on 'composite energy well' model
A recent study reported a new approach that can effectively inhibit the migration and agglomeration of supported nanoparticles by fabrication of a model catalyst Pt/CeO2/NiAl2O4/Al2O3@SiO2.

New assay assesses multiple cellular pathways at once
A novel technological approach developed by researchers at Baylor College of Medicine expands from 2 to 6 the number of molecular pathways that can be studied simultaneously in a cell sample with the dual luciferase assay, a type of testing method commonly used across biomedical fields.

Personalized assay surpasses limits for detecting tumor DNA in breast cancer patients
Scientists have developed a personalized platform tailored to patients' specific cancer mutations named TARDIS, which was able to accurately detect circulating tumor DNA (ctDNA) and signs of residual disease in 33 women with breast cancer.

Read More: Assay Based News and Assay Based Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.